β-CA-specific inhibitor dithiocarbamate Fc14–584B: a novel antimycobacterial agent with potential to treat drug-resistant tuberculosis

Inhibition of novel biological pathways in Mycobacterium tuberculosis (Mtb) creates the potential for alternative approaches for treating drug-resistant tuberculosis. In vitro studies have shown that dithiocarbamate-derived β-carbonic anhydrase (β-CA) inhibitors Fc14–594 A and Fc14–584B effectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Aspatwar, Ashok, Hammarén, Milka, Koskinen, Sanni, Luukinen, Bruno, Barker, Harlan, Carta, Fabrizio, Supuran, Claudiu T., Parikka, Mataleena, Parkkila, Seppo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445161/
https://www.ncbi.nlm.nih.gov/pubmed/28629306
http://dx.doi.org/10.1080/14756366.2017.1332056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445161/
https://www.ncbi.nlm.nih.gov/pubmed/28629306
http://dx.doi.org/10.1080/14756366.2017.1332056

Ejemplares similares